Quincy Attobrah

The FDA approved Revtorpyk with fulvestrant, with or without Ibrance, for certain patients with advanced HR-positive, HER2-negative breast cancer.

The FDA approved Keytruda plus Padcev before and after bladder surgery for adults with muscle-invasive bladder cancer, expanding treatment options.

The FDA approved Sarclisa Escena, a new subcutaneous treatment option for adults with multiple myeloma across newly diagnosed and relapsed settings.

Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect at each step.

EPKINLY Plus REVLIMID Improves Progression-Free Survival in Relapsed Diffuse Large B-Cell Lymphoma

FDA approves Tregzi, a new cell therapy that helps reduce chronic graft-versus-host disease after donor stem cell transplant in adults with blood cancers.

FDA approves Trodelvy alone or with Keytruda for the first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer.

Susan Yaguda, oncology nurse at Atrium Health Levine Cancer Institute, transforms cancer care by treating the whole person — mind, body, and spirit — one patient at a time.

FDA approves Ibrance with trastuzumab and endocrine therapy for maintenance treatment of HR-positive, HER2-positive metastatic breast cancer.

FDA grants full approval to TECELRA and expands its use to eligible patients ages 12 and older with advanced synovial sarcoma after chemotherapy.

A pediatric oncologist opens up about what draws her to one of medicine's hardest jobs, and what keeps her going.

A pediatric oncologist explains how scalp cooling, fertility preservation and early planning protect children with cancer well beyond treatment.

The former Real Housewives star opens up about her melanoma journey, the nurses who kept her sane, and why vulnerability might be the most powerful health tool there is.

FDA approves Welireg plus Keytruda for adults with high-risk renal cell carcinoma following nephrectomy based on phase 3 LITESPARK-022 trial results

Five-year KEYNOTE-942 data show a personalized cancer vaccine plus Keytruda reduced recurrence risk in patients with high-risk melanoma.

Monjuvi and Revlimid plus R-CHOP helped patients with high-risk diffuse large B-cell lymphoma stay in remission longer and reduce relapse risk.

Trodelvy plus Keytruda extended benefit beyond progression in PD-L1-positive metastatic triple-negative breast cancer.

Keytruda plus Lynparza showed clinical activity but missed its primary efficacy goal in BRCA-mutated metastatic pancreatic cancer.

Teen cancer survivor Brynn and friend Teddy created Soothe Note, a free app helping patients track symptoms and prepare for appointments.

Exercise after colon cancer chemotherapy reduced recurrence risk, improved survival and quality of life, according to the CHALLENGE trial.

Giredestrant plus Afinitor may help patients with metastatic breast cancer delay chemotherapy and stay on effective treatment longer.

Patients with EGFR exon 20-positive NSCLC had longer progression-free survival with Zegfrovy than chemotherapy.

First-in-human pancreatic cancer trial at WVU tests an implant that delivers chemotherapy directly into tumors using low-voltage electric pulses.

FDA approves Imfinzi plus BCG for adults with high-risk non-muscle invasive bladder cancer based on phase 3 POTOMAC trial results.

A healthy, active 39-year-old shares how blood in his urine led to a bladder cancer diagnosis and becoming first in Texas to receive Inlexzo.

ASCO 2026 will feature new gynecologic cancer research, including advances in immunotherapy, ADCs, vaccines and targeted therapies.

After losing his mother to colorectal cancer, Colorectal Cancer Alliance CEO Michael Sapienza turned grief into advocacy to improve screening, treatment and patient care.

Colonoscopies can do more than detect colorectal cancer early — they can prevent it by removing precancerous polyps before cancer develops.

Zynyz plus chemotherapy improved overall survival for patients with advanced anal cancer in the phase 3 POD1UM-303/InterAACT-2 trial.

New research suggests gut bacteria may play a role in fatigue and pain experienced by melanoma patients receiving immunotherapy.